

CSD/NSE/2022-23  
April 01, 2022

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**  
**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Increase in Volume**  
**Ref: NSE/CM/Surveillance/11748, your email dated 31/03/2022**

---

With reference to above mentioned subject, we write to inform that our company has been notifying to the stock exchanges all the events, information which comes under the purview of Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time.

At this point of time we do not have any material announcement/ event due for notification to the stock exchanges under Regulation 30 of SEBI LODR Regulations which may have a bearing on the price or volume behavior of the scrip. The increase in the price/volume of our security in the recent past appears to be based on market speculation and we have no other comment to offer on this development.

We request you to disseminate this clarification on your website for information of general public, which is also being uploaded on our Company's website.

Thanking you.

Yours faithfully,  
For **Suven Life Sciences Limited**



**Shrenik Soni**  
Company Secretary

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com